SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

JK-P3

Item No. 37555

CAS Registry No.:	942655-44-9
Formal Name:	3,4-dimethoxy-N-(5-phenyl-1H-pyrazol-3-yl)-benzamide
MF:	$C_{18}H_{17}N_3O_3$
FW:	323.4
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JK-P3 is supplied as a solid. A stock solution may be made by dissolving the JK-P3 in the solvent of choice, which should be purged with an inert gas. JK-P3 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of JK-P3 in these solvents is approximately 30 mg/ml.

Description

JK-P3 is an inhibitor of the tyrosine kinases VEGFR2, FGFR1, and FGFR3 (IC_{50}s = 7.83, 27, and 5.18 µM, respectively).[1] It decreases VEGF-A-induced VEGFR2 phosphorylation in human umbilical vein endothelial cells (HUVECs) when used at a concentration 10 µM. JK-P3 decreases the proliferation of HCT116, SW480, and HT-29 colon cancer cells (IC_{50}s = 24.26, 27.2, and 29.65 µM, respectively), as well as A549 lung cancer cells (IC_{50} = 30.49 µM).[2] It decreases wound closure percentage in a scratch assay, as well as endothelial branch length and branch points formed by VEGF-A-stimulated HUVECs when used at a concentration of 10 µM.[1]

References

1. Kankanala, J., Latham, A.M., Johnson, A.P., *et al.* A combinatorial *in silico* and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis. *Br. J. Pharmacol.* **166(2)**, 737-748 (2012).
2. Dong, Y., Liu, M., Mao, Y., *et al.* Discovery of 2-(isoxazol-5-yl)phenyl 3,4-dihydroxybenzoate as a potential inhibitor for the Wnt/β-catenin pathway. *Bioorg. Chem.* **128**, 106116 (2022).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM